The present study used prostate cancer LNCaP cells to investigate whether the drugs that are frequently prescribed to patients, and collected at the pharmacy of Gifu Pharmaceutical University (Gifu, Japan), altered the expression level of PSA in prostate cancer LNCaP cells. Here, KLK3 is linked to prostate cancer.